3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Neuroendocrine Tumors
6
Carcinoma, Hepatocellular
2
Carcinoid Tumor
2
Serotonin Syndrome
1
Peritoneal Neoplasms
1
Neuroendocrine Tumour With Carcinoid Symptoms
1
Neoplastic Cells, Circulating
1
Neoplasms
1
Intestinal Obstruction
1
Gastro-enteropancreatic neuroendocrine tumor
1
Flushing
1
Endocrine Tumors
1
Diarrhea
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Acromegaly
1
Interventions
Irinotecan
4
Octreotide
3
Probiotics
2
Leucovorin
2
Fluorouracil
2
shosaiko-to
1
maltodextrin
1
lanreotide
1
isatuximab
1
bile acid binding proteins
1
Temozolomide
1
Sulfasalazine
1
Raloxifene Hydrochloride
1
Radiation
1
Oxaliplatin
1
Loperamide
1
Long-Term Synaptic Depression
1
Levofloxacin
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Diet Therapy
1
Cyclophosphamide
1
Colesevelam Hydrochloride
1
Celecoxib
1
Cefpodoxime
1
Cefixime
1
Calcium Aluminosilicate
1
Anti-Bacterial Agents
1
Acupuncture Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Diarrhea
×
lanreotide
×
Clear all
NCT00774930
2022-10-14
ELECT
Ipsen
Phase 3
Completed
115 enrolled
17 charts